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Abstract
Background: Hypoglycaemia is an independent risk factor for death in severe malaria and a recognized adverse
treatment effect of parenteral quinine. In 2006 our hospital changed quinine treatment policy from 15 mg/kg
loading (plus 10 mg/kg 12-hourly) to 20 mg/kg loading (plus 10 mg/kg 8-hourly) to comply with new WHO
guidelines. This presented us with the opportunity to examine whether there was any dose relationship of quinine
and hypoglycaemia occurrence.
Methods: Retrospective case notes review of all children admitted to hospital with severe falciparum malaria
between April 2002 - July 2009, before and after the introduction of the new WHO quinine regimen. Four-hourly
bedside glucose levels were measured until intravenous quinine was discontinued. Clinical events immediately
preceding or concurrent with each episode of hypoglycaemia (glucose < = 3.0 mmol/l) were recorded.
Results: 954 children received the old quinine regime and 283 received the new regime. We found no evidence
of an increased prevalence of hypoglycaemia (< = 3.0 mmol/L) on the new regime compared to former (15% vs.
15%); similar findings were noted for profound hypoglycaemia (< 2.2 mmols/L) 8% v 5%, P = 0.07. Episodes were
co-incident with disease severity markers: coma (57%), circulatory failure (38%) and respiratory distress (21%) but
less commonly with seizures (10%). Disruption of maintenance fluids and/or blood transfusion concurred with 42%
of the hypoglycaemia episodes. Post admission hypoglycaemia increased odds of fatal outcome (24%) compared
to euglycaemic counterparts (8%), odds ratio = 3.45 (95% confidence interval = 2.30-5.16) P < 0.01.
Conclusion: There was no evidence to indicate a dose relationship between quinine and occurrence of
hypoglycaemia. Hypoglycaemia concurred with severity features, disruption of glucose infusion and transfusion.
Careful glucose monitoring should be targeted to these complications where resources are limited.
Background
Hypoglycaemia is an important complication of severe
Plasmodium falciparum malaria, particularly in children
and pregnant women. The prevalence of hypoglycaemia
appears to vary in different parts of the world and in
different age groups ranging from 8% in SE Asian adults
[1] to 10-20% in African children [2-5]. Hypoglycaemia
in children is independently associated with poor out-
come [6-8] and an increased mortality [2,9-11] predomi-
nantly when accompanied by acidaemia (pH < 7.3) or
hyperlactataemia (lactate > 5 mmol/l) [12,13].
Hypoglycaemia occurs both on presentation to hospi-
tal and during the course of admission in children with
severe malaria. The aetiology is incompletely understood
and is likely to be multifactorial. Depletion of glucose
stores due to starvation, parasite utilisation of glucose,
cytokine-induced impairment of gluconeogenesis have
been implicated [14]. Hyperinsulinaemia, secondary to
quinine therapy, has been advanced as an iatrogenic
cause and is well established in adults [15,16]. Data on
its relationship in African children with severe malaria
are relatively few, but what does exist indicates that
hyperinsulinaemia rarely accompanies hypoglycaemia
either at admission or during quinine treatment [3,17].
However, considerable concern still exists and intrave-
nous dosing is strongly recommended in solutions con-
taining dextrose to avert the risk of hypoglycaemia [18].
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There have been no studies that have explored dose
dependency of quinine and the occurrence of hypogly-
caemia. In 2006, Kilifi District Hospital (KDH) adopted
the new World Health Organization (WHO) guidelines
for parenteral quinine treatment of severe falciparum
malaria, which recommended 20 mg/kg loading dose of
quinine followed by 10 mg/kg 8-hourly [18]. Our pre-
vious regime, based on pharmacokinetic studies
by Winstanley et al [19,20], initiated treatment with a
15 mg/kg loading dose followed by 10 mg/kg twice daily
had been in used since 1998. The objective of this study
was to examine the relationship of quinine dosage and
occurrence of hypoglycaemia by examining the fre-
quency of hypoglycaemia in children treated with either
of the two regimes. We investigated clinical events and
factors temporally associated with the development of
hypoglycaemia during the course of admission.
Methods
The study entailed a retrospective review of case notes
for two groups of children (0-12 years) with severe
malaria admitted to the paediatric high dependency unit
(HDU) of Kilifi District Hospital that is run by Kenya
Medical Research Institute/Wellcome Trust Programme,
Kenya. All paediatric admissions have a standard admis-
sion proforma completed and baseline laboratory inves-
tigations. All children presenting for admission to
hospital, are triaged, to identify those with life-threaten-
ing complications and those who comply with the defi-
nition of severe malaria are promptly transferred
following stabilisation to our high dependency unit. Par-
ental consent for clinical descriptive surveillance or
audit is obtained for all infant paediatric admissions.
Ethical approval for ongoing surveillance has been
granted by the Kenya Medical Research Institute
(KEMRI) ethics committee. The case notes of unselected
children fulfilling strictly-defined criteria for severe
malaria (P. falciparum parasitaemia plus impaired con-
sciousness and/or respiratory distress)[6] were reviewed
for this study. Impaired consciousness was defined as
Blantyre coma score (BCS) < = 2, or prostration (inabil-
ity to breast feed if < 9 months, or inability to sit unsup-
ported if > = 9 months). Respiratory distress identified
children with deep ‘Kussmaul’ breathing, a clinical
feature of metabolic acidosis and an independent risk
factor for fatal outcome [6]. Mid Upper Arm circumfer-
ence (MUAC) < 12 cm, visible severe wasting and/or
the presence of oedema (defining kwashiorkor) were
used to pragmatically identify the malnourished children
[21]. Two time periods were considered: April 2002 -
April 2006 cohort which included 954 children treated
with the previous quinine regimen (15 mg/kg intrave-
nous loading dose and a maintenance dose of 10 mg/kg
12-hourly) diluted in 5% dextrose and infused
intravenously over 2 hours; and May 2006 - July 2009
cohort which included 283 children treated with the
new WHO recommended quinine regimen (20 mg/kg
intravenous loading dose and a maintenance dose of 10
mg/kg 8-hourly) diluted in 5% dextrose and infused
intravenously over 4 hours. Quinine used in both peri-
ods was obtained from a single supplier (Indus Pharma
Ltd, Pakistan) together with their respective certificates
of analysis for each batch.
Standard treatment included intravenous maintenance
fluids (5% dextrose and 0.18% saline at 4 mls/kg/hour),
intravenous quinine, and antibiotics. Appropriate treat-
ment was started immediately after admission. This cur-
rent study did not include any child admitted to the
general ward with malaria parasitaemia who deteriorated
after admission fulfilling the definition of severe malaria,
albeit relatively few. Parenteral drugs and intravenous
fluids were prescribed until the child was able to take
and retain oral fluids and medication. Oral anti-malarial
medication prescribed depended on the national treat-
ment policy at the time and included sulfadoxine pyri-
methamine (2002-2005) or artemether-lumefantrine
(2006-2009). At admission blood glucose was measured
in the laboratory using an automated glucose oxidase
system (Analox instrument (Analox(r) London, UK)).
Thereafter blood glucose was routinely monitored using
the bedside monitoring device Accu-Chek™ Advantage
(Roche diagnostics, Sydney, Australia; precision of 0.1
mmolL) at one hour post admission and four-hourly
until cessation of quinine. Hypoglycaemia, defined as a
blood glucose less than or equal to 3 mmol, determined
by either device, was managed with an intravenous
bolus of 5 ml/kg of 10% dextrose which has been the
standard of care in the HDU since 2000 [18]. Additional
measurements were conducted during episodes of sei-
zure or posturing activity, transfusion or clinical dete-
rioration. The Accu-Chek™ machine was calibrated
weekly and every time a new box of test strips was
opened.
In-patient medical and nursing case notes and obser-
vation charts for all children admitted with severe
malaria over the period of the study were reviewed to
identify and confirm episodes of hypoglycaemia (capil-
lary or venous blood glucose equal or less than
3.0 mmol/l) that occurred post-admission and therefore
after commencement of parenteral quinine. Clinical
events occurring around each hypoglycaemia episode
(4 hrs before and one hour after the episode) were
examined and recorded. We also examined the fre-
quency of hypoglycaemia cases for three different defini-
tion thresholds; < 2.2 mmol/l (severe hypoglycaemia), <
2.5 mmol/l (moderate hypoglycaemia), and < = 3 mmol/
l (any hypoglycaemia). In clinical practice different
blood glucose thresholds are used to define
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hypoglycaemia. Studies have shown that hypoglycaemia
< 2.2 mmols/L is associated with poor outcome [22] and
this complication is incorporated within the case defini-
tion of severe malaria in children and adults [23]. Inter-
national paediatric guidelines recognize a blood glucose
of < 3 mmols/L, in children with severe disease as a
therapeutic indication for treatment [24]. We adopted
this practice in 2002 for all severely ill children. The
WHO guidelines, on the other hand, recommends < 2.5
mmol/l threshold for treatment of hypoglycaemia in
children with severe illness [18].
There was incomplete data on the prevalence of neu-
rological sequelae after discharge and therefore this data
was not included.
Statistical analysis
Baseline characteristics were compared between the two
groups (regimens). Proportions were compared for cate-
gorical variables using Chi-square tests and Fisher’s
exact where appropriate. Malaria parasitaemia was sum-
marised as a geometric mean [95% reference range]. For
continuous variables, Student’s t-test was used to com-
pare mean differences between the two regimens. In any
case of non-normal data, Mann Whitney (Wilcoxon
Rank sum) test was used to make comparison between
the two groups. Relative risk of hypoglycaemia in the
two treatment groups was also estimated. Clinical defini-
tions of severity features and our definition of circula-
tory collapse (hypovolaemic shock) have been described
previously [13,23]. Variables with clinical plausibility or
that were imbalanced at baseline between the two
groups were chosen for univariable analysis to test asso-
ciation with post-admission hypoglycaemia. Those vari-
ables with p-values ≤ 0.15 were chosen for inclusion in
the multivariable logistic regression to adjust for con-
founding. Variables were adjusted for age in the multiple
regression analysis. The regression model was tested for
specification error and goodness of fit. Significance was
evaluated at 5% level. Analysis was done using Stata ver-
sion 11 (Stata corporation, Texas, United States).
Results
A total of 954 children were treated with the old regi-
men (April 2002 to April 2006) and 283 children were
treated with the new regimen (May 2006 - July 2009).
Male children comprised 50% of cases in both cohorts.
Children treated with the old regimen cohort were
younger, median age 28 months (IQR 18 - 43) com-
pared to the new regimen 36 months (IQR 25 - 48), p <
0.01. Detailed admission characteristics for the children
in two cohorts are shown in Table 1. Children in the
2006-2009 cohort had higher parasitaemia but a lower
Table 1 Admission characteristics for children in the two cohorts
Clinical features Quinine 15 mg/kg (N = 954) n (%) Quinine 20 mg/kg (N = 283) n (%) P-value Ŧ
Coma (BCS ≤ 2) 434/953 (46) 123/279 (44) 0.67
Deep breathing 391/953 (41) 95/277 (34) 0.04
Impaired consciousness 706/953 (74) 204/279 (73) 0.91
Severe anaemia (Hb < 5 g/dl) 229/949 (24) 47/279 (17) 0.01
Temperature gradient 263/951 (28) 55/277 (20) 0.009
Delayed capillary refill (> 2 seconds) 232/953 (24) 41/279 (15) 0.001
Weak Pulse volume 159/953 (17) 31/277 (11) 0.03
Mid Upper Arm Circumference < 12 cm 59/914 (6) 9/240 (4) 0.11
Visible wasting 58/953 (6) 6/277 (2) 0.01
Seizures 168/953 (18) 38/277 (14) 0.13
Prostration 436/953 (46) 104/279 (37) 0.05
Hypoglycaemia < = 3 mmol/l 155/952 (16) 26/282 (9) 0.003
Severe hypoglycaemia (< 2.2 mmol/l) 118/952 (12) 19/282 (7) 0.008
Creatinine > 80 mmol/l 225/904 (25) 49/211 (23) 0.61
Potassium > 5 mmol/l 149/934 (16) 17/259 (7) < 0.01
Mean laboratory variable [SD]
Haemoglobin level, mg/dl 7.06 [2.63] 7.53 [2.44] 0.004
pH 7.28 [0.14] 7.30 [0.51] 0.34
pCO2,mmol/L 4.17 [1.92] 3.98 [1.73] 0.18
Base Deficit, mmol/L 9.99 [6.63] 8.49 [5.72] 0.002
Sodium level, mmol/l 134.33 [5.62] 133.39 [5.51] 0.02
Creatinine level, mmol/l 68.89 [41.7] 66.81 [32.65] 0.49
Parasitaemia ×103parasites/μl 3651 [3149 - 4234] 5604 [4393 - 7150] 0.01
IQR - Inter-quartile range, SE-Standard error, Ŧ Test statistic - c2 test or t-test on means
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proportion of severity indicators (coma, deep breathing,
severe anaemia and hypoglycaemia) than the 2002- 2006
cohort (Table 1). Severe hypoglycaemia (< 2.2 mmols/L)
was also more common at admission in the 2002-2006
cohort than in the 2006-2009 cohort: 119 (12%) versus
19 (7%) (p = 0.007), respectively.
Frequency of hypoglycaemia post admission
Fifteen percent (145/954) of the 2002-2006 cohort
developed hypoglycaemia (< = 3 mmols/l) post admis-
sion as did 15% (42/283) of the 2006-2009 cohort OR =
0.97, 95% confidence interval [0.67-1.41]; P = 0.88. The
prevalence of hypoglycaemia, if compared with baseline
levels, increased overall by 6% (from 9% at admission) in
the 2006-2009 cohort, but decreased by 1% in the 2002-
2006 cohort post admission (from 16% at admission). Of
the 145 children in the 2002-2006 cohort who devel-
oped hypoglycaemia after treatment, 103 (71%) were
euglycaemic at admission and 42 (29%) had hypoglycae-
mia at baseline. Sixty eight percent (99/145) of these
children had a single episode and 46 (32%) had multiple
episodes. Of the 42 children in the 2006-2009 cohort
who developed hypoglycaemia after treatment, 27 (66%)
were euglycaemic at admission whilst 14 (34%) had
hypoglycaemia at admission. Fifty two percent (22/42) of
the children had a single episode whilst the remaining
20 (48%) had multiple episodes. Overall, children pre-
senting with hypoglycaemia at admission had increased
odds of having an episode post admission, OR = 3.18
(CI 2.21 - 4.58, p < 0.0001). For children who were
euglycaemic at admission there was no statistical differ-
ence in frequency of subsequent episodes between the
two cohorts (p = 0.32). When comparing the numbers
with multiple episodes of hypoglycaemia post admission
between the two cohorts, there was weak evidence of a
slight increase during the new regime (p = 0.06). Figure
1 shows the frequency of single and multiple episodes in
the two cohorts.
Timing and distribution of hypoglycaemia episodes
The distribution and timing of hypoglycaemia episodes
was explored and the results are shown on Table 2. We
found no statistical difference in the timing of the events
between the two cohorts (c2 for trend, p = 0.15)
although the children who developed hypoglycaemia
receiving the new regimen (2006-2009 cohort) had a
higher proportion of the first episode occurring after 24
hours (OR: 0.57; 95% CI: [0.26 - 1.24]).
Severity of Hypoglycaemia
Using the strict definition for severe hypoglycaemia
(< 2.2 mmol/l) a lower proportion of children developed
profound hypoglycaemia, 13/283 (5%) on the new
regimen group compared to the old regimen group
(2002-2006 cohort), 74/954 (8%) (OR: 0.57; 95% CI:
[0.32 - 1.04], P = 0.07). Using a slightly less stringent
Figure 1 Frequency of episodes in the two cohorts: Quinine 15 mg/kg n = 145, Quinine 20 mg/kg n = 42.
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threshold (< 2.5 mmol/l) we found little difference in
the numbers developing hypoglycaemia (22/283, 8%) on
new regimen compared to (103/954, 11%) on the old
regimen (OR: 0.70; 95% CI: [0.43 - 1.12], P = 0.14).
Table 2 summarises the distribution and severity of the
episodes of hypoglycaemia post admission and Figure 2
shows the frequency of hypoglycaemia using the differ-
ent cut-offs in the two cohorts.
Table 2 Time of occurrence of first hypoglycaemia episode and hypoglycaemia severity
2002-2006 cohort: Quinine 15 mg/kg regimen 2006-2009 cohort: Quinine 20 mg/kg regimen
Time period Frequency by first episode
(n = 145)
n (%)
Frequency by all episodes
(n = 229)
n (%)
Frequency by first episode
(n = 42)
n (%)
Frequency by all episodes
(n = 86)
n (%)
0 - 24 hrs 118 (81) 157 (69) 30 (71) 47 (55)
After 24 hrs 19 (13) 41 (18) 6 (14) 21 (24)
After 48 hrs 8 (6) 31 (14) 6 (14) 18(21)
Severity (Blood glucose levels), n/N (%)
< 2.2 mmol/l 74/954 (8) 13/283 (5) P = 0.07
< 2.5 mmol/l 103/954 (11) 22/283 (8) P = 0.14
< = 3.0 mmol/l 145/954 (15) 42/283 (15) P = 1.00
Final outcome (death) - those with and those without any hypoglycaemia post admission, n/N (%)
Hypoglycaemia =
Yes
29/145 (20) 15/42 (36) P = 0.04
Hypoglycaemia =
No
73/809 (9) 13/240 (5) P = 0.07
Final outcome (death) - those with and those without any hypoglycaemia at or during admission, n/N (%)
Hypoglycaemia =
Yes
45/155 (29) 11/26 (42) P = 0.18
Hypoglycaemia =
No
57/797 (7) 17/255 (7) P = 1.00
Figure 2 Frequency of hypoglycaemia severity using different definitions. The x-axis includes blood sugar thresholds of < = 3 mmols/L, 2.5
mmols/L and < 2.2 mmols/L.
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Mortality and Clinical associations
In-hospital case fatality was similar in the respective
cohorts, 102/954 (11%) and 28/283 (10%) (c2 = 0.13, p
= 0.71). For both cohorts the development of any epi-
sode of hypoglycaemia (< = 3 mmols/L) after admission
was associated with an increased odds of dying when
compared to those who remained euglycaemic, 44/187
(24%) and 86/1049 (8%) respectively, OR = 3.45 (95%
confidence interval = 2.30-5.16), (P < 0.01).
Clinical events concurring with episodes of hypogly-
caemia in both cohorts included coma (defined as BCS
< = 2) in 57% of the episodes; evidence of circulatory
failure (hypovolaemic shock) in 38% of episodes; 21%
were associated with clinical features of metabolic acido-
sis (deep breathing). In addition, 24% (45/187) of epi-
sodes occurred during a blood transfusion whilst 37%
(70/187) of the episodes occurred during a period of
inadequate glucose supply (accidental or actual disconti-
nuity of intravenous maintenance glucose). Episodes of
seizures and/or posturing were less frequently associated
with hypoglycaemia; they were co-incident in 10% and
9% of the hypoglycaemia episodes, respectively. Our pre-
liminary exploration of the data which examined only
the first episode of hypoglycaemia (< = 3 mmols/L) after
admission indicated little differences in the frequency of
these associated clinical factors between the two
cohorts.
Predictors of hypoglycaemia post admission
In the age-adjusted analysis of the predictors of hypogly-
caemia post admission, the following factors were asso-
ciated with increased risk of developing hypoglycaemic
post admission: hypoglycaemia at admission, deep
breathing, severe anaemia, temperature gradient (a sign
of impaired perfusion and pragmatically assessed by
running the back of the hand from the foot up the shin:
where the foot was cooler than the shin this indicates a
temperature gradient) and weak pulse volume (an
advanced sign of hypovolaemic shock) (Table 3). Multi-
variable logistic regression was used to adjust for vari-
ables that were predictive in the univariable analysis
(variables with p values < 0.15). The following variables
were significant predictors of hypoglycaemia post admis-
sion at multiple regression analysis: hypoglycaemia at
admission, severe anaemia and temperature gradient (all
adjusted for age in months).
Discussion
Despite some recent and localized successes in disease
control severe malaria remains a major public health
burden in sub Saharan Africa killing over half million
children each year [23]. Parenteral quinine is therefore
one of the most widely used treatment in African hospi-
tals and information about the potential iatrogenic side
effects remain pertinent. Our study provides valuable
information for clinicians treating children with severe
malaria in Africa with respect to the occurrence of life-
threatening hypoglycaemia and its clinical associations.
Hypoglycaemia occurs in 15% of children following
admission, with over 70% of episodes occurring within
24 hours of admission. We found no evidence of a
dose-response relationship between quinine and any
degree of hypoglycaemia after admission. The most
important clinical variables at admission that predicted
development of hypoglycaemia after admission were
hypoglycaemia, severe anaemia and temperature gradi-
ent (a marker of impaired perfusion or circulatory fail-
ure). Most episodes were single events and frequently
concurrent with one or more markers of disease severity
including coma, clinical features of impaired perfusion,
deep breathing (Kussmaul breathing) but less commonly
associated with the time-honoured suspected clinical
Table 3 Predictors of Hypoglycaemia post admission
Univariable analysis Multiple regression analysis
Unadjusted OR [CI] P-Value Adjusted OR [CI]* P-Value
Treatment:Regimen 0.97 [0.67 - 1.41] 0.88 - -
Hypoglycaemia at admission 3.18 [2.21 - 4.58] < 0.001 2.76 [1.87 - 4.06] < 0.001
Deep breathing 1.46 [1.06 - 1.99] 0.02 0.96 [0.67 - 1.36] 0.80
Severe anaemia 1.91 [1.36 - 2.69] < 0.001 1.57 [1.08 - 2.29] 0.02
Temperature Gradient 2.10 [1.51 - 2.92] < 0.001 1.77 [1.22 - 2.57] 0.003
Delayed Capillary refill time 1.63 [1.15 - 2.31] 0.006 1.00 [0.65 - 1.55] 0.98
Visible wasting 1.78 [0.98 - 3.25] 0.06 1.32 [0.69 - 2.54] 0.40
Prostration 0.88 [0.64 - 1.20] 0.41 - -
Weak pulse volume 1.63 [1.11 - 2.41] 0.01 0.93 [0.58 - 1.49] 0.75
Parasitaemia# 1.29 [0.86 - 1.95] 0.22 - -
*Adjusted for age in months; OR - Odds ratio; CI - Confidence Interval.
Treatment, prostration and parasitaemia not included in the multivariable model as p > 0.15.
#Parasitaemia was categorised as below or above 5000 parasites/microlitre.
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associations of seizures or posturing. We found a coinci-
dence of hypoglycaemic episodes during transfusions or
periods of disruption of intravenous glucose infusion.
Overall, fatal outcome was more common in children
developing hypoglycaemia after admission than their
euglycaemic counterparts.
Our previous regime, based upon pharmacokinetic
studies, indicated that lower doses were warranted due
to a smaller apparent volume of distribution in the chil-
dren, and that a higher dosage regime was justifiable for
adults and in areas where quinine-resistance was more
problematic [19]. A recent large trial in Asia (SEQUA-
MAT) showed that parenteral artesunate reduced mor-
tality by 35% compared to conventional quinine
treatment [25]. SEQUAMAT, together with previous
studies, have shown a lower frequency of hypoglycaemia
in the artesunate treated group [26-29]. Our data, and
that of previous studies, do not suggest any dose-
dependent relationship with quinine treatment in Afri-
can children with severe malaria. For this and many
other reasons a separate trial in African children is
underway (AQUAMAT ISRCTN 50258054).
Hypoglycaemia remains a common complication of
severe malaria, occurring throughout the clinical course.
The origin, in African children, is unlikely to be iatro-
genic. Studies comparing children with severe malaria
and other severe illnesses found no difference in the fre-
quency of this complication, indicating that it is a con-
sequence of multi-organ involvement manifest in severe
life-threatening illness [11]. Plasma glucose concentra-
tion reflects the balance between glucose supply and
glucose use in children with severe illness including
malaria. Inadequate glucose supply and fasting have
been implicated in a number of studies in children with
severe malaria [11,30] but others examining glucose
kinetics conclude that gluconeogenesis and endogenous
glucose production is preserved or even increased
[28,31] but glucose supply however, is disproportionately
derived from glycogenolysis. Zijlmans and colleagues
recently demonstrated that even after 16 hours of fasting
glycogenolysis contributed to 35-40% of the glucose pro-
duction [32]. This finding is surprising given that it had
been previously assumed that the glycogen stores in
young children are believed to support a maximum fast-
ing period of 12 hours [33]. In our study we found that
discontinuation of a 5% glucose infusion either prema-
turely in a fasting child, during a transfusion or acciden-
tally (non-patency of an intravenous cannula) was one
of the events that were commonly observed in associa-
tion with hypoglycaemia. Nutritional status is an impor-
tant determinant of glycogen stores, which may be
critical in a severely ill child. Most of our cohort had
mild to moderate undernutrition, with the median
weight for height or length z-score (WHZ-score) -1.5
[IQR (-2.4, -0.65)], which may explain why fasting was
associated with early hypoglycaemia (within the four
hours period of the event) and at variance with the stu-
dies in Surinamese children, whose median WHZ-score
was 0.6 [32]. These observations concur with our earlier
studies indicating that whilst glucose production is
increased in severe malaria it fails to compensate to the
increased demand and therefore puts children at risk of
developing hypoglycaemia [30]. For children receiving
blood transfusion, which ought to contain adequate dex-
trose/citrate to prevent hypoglycaemia, either the stress
of transfusion or relative inadequacy of glucose supply
may lead to a higher risk of hypoglycaemia in a severely
ill child. Whilst inappropriate transfusions should be
discouraged we strongly recommend additional glucose
monitoring of children receiving blood transfusion.
The characteristic clinical manifestations of hypogly-
caemia are rarely evident owing to disease severity and
careful monitoring is recommended to facilitate early
diagnosis and prevent poor outcome and neurological
sequelae [34-36]. There is need for more evidence from
randomised trials to define the ideal threshold for treat-
ment of hypoglycaemia as recent observational studies
have shown that mortality is still higher at a threshold
greater than 3.0 mmol/l. A recent review by Achoki and
colleagues demonstrated in a prospective cohort study
of all paediatric admissions that blood glucose concen-
trations at admission of up to 4.0 mmol/l was associated
with increased odds of mortality compared to all levels
of glucose concentration above this threshold [37].
Another recent study conducted in Mali by Willcox and
colleagues demonstrated that low glycaemia (2.2-4.4
mmol/l) was significantly associated with odds of mor-
tality in children with a clinical diagnosis of severe
malaria [38]. The authors concluded that the optimum
threshold is 6.1 mmol/l for predicting mortality which is
much higher than current definitions.
Our study has a number of limitations. First, the ret-
rospective design, rather than a randomised trial, meant
that the two study cohorts were not identical in terms
of overall disease-severity indices. The children in the
2006- 2009 cohort were on average older, had fewer
severity indicators at admission but survival was similar
in the two groups. The clinical associations with hypo-
glycaemia after admission were identical and reassur-
ingly the occurrence of severe hypoglycaemia was less
apparent in the latter cohort. Secondly, glycaemic con-
trol was monitored using bedside handheld glucometers.
The performance of point of care devices in accurately
determining hypoglycaemia has been questioned [39],
since they have been associated with underestimation of
hypoglycaemic events, particularly in patients with mod-
erate to severe anaemia. Recent studies have demon-
strated that moderate to severe anaemia explains most
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of the major variance between glucometer and quality
control laboratory readings [40]. For patients with a hae-
matocrit below 20 the percentage error of glucometer
measurements, compared to the reference laboratory
glucose, was nearly 30% [40]. In our study, monitoring
was largely by hand held devices, although this may
have introduced a systematic error in glucose readings,
the glucometers used in both cohorts were identical and
therefore unlikely to have biased the comparison.
Another limitation was the unequal numbers in the two
cohorts. There were fewer cases of severe malaria in the
2006 - 2009 cohorts and this reflects the changing trend
in malaria epidemiology in the study area [41].
Conclusions
We found no relationship between quinine dosage and
the frequency or severity of hypoglycaemia in African
children with severe malaria. Overall 15% of children
with severe malaria developed hypoglycaemia after
admission most commonly on the day of admission.
Hypoglycaemia occurrence was temporally associated
with markers of disease severity and disruption in the
maintenance glucose supply. Owing to the poor out-
come a case fatality of 24% compared to 8% in euglycae-
mia children indicate the need for targeted glucose
monitoring in children who remain severely ill and pre-
vent premature termination of glucose maintenance
infusion. Further research, including controlled trials, to
establish best practice is urgently needed.
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